The dispute, which originated in 2021, centered on the Grosveld Patent, a core piece of intellectual property developed by Professor Frank Grosveld. By finding the infringement willful, the jury has opened a path for Harbour BioMed to petition the court to treble the damages, which could see the total payout climb to $60.6 million. This outcome stands out in the District of Delaware, where such substantial jury awards in complex patent litigation remain rare.
In section Releases
Harbour BioMed Wins $20M Patent Case Against Amgen
A Delaware jury has ruled that Amgen and its subsidiary Teneobio willfully infringed on a foundational antibody discovery patent held by Harbour BioMed. The verdict, delivered after a brief three-hour deliberation, awards the biopharmaceutical company $20.2 million and validates the integrity of its proprietary transgenic rodent technology.
Dr. Jingsong Wang, CEO of Harbour BioMed, described the verdict as a validation of the company's scientific contributions and strategic resilience. The company pivoted its legal approach shortly before the trial, focusing its efforts on a specific patent while preserving the right to appeal broader claims. With this victory secured, Harbour BioMed is already signaling further litigation, targeting a separate patent in its portfolio that the company estimates could carry financial implications ten times greater than the current award.
Comments (0)
No comments yet. Be the first!